MedBridge Shanghai · International medical facilitation platform recognized under Shanghai Government Document No. 32
Back to home
Xiamen Humanity Hospital (BNCT Center)

Grade III · China’s first AB-BNCT center

Xiamen Humanity Hospital (BNCT Center)

Nasopharyngeal cancerBrain tumorSarcoma

Established

2014

Beds

180+

Annual Volume

2,400+

Xiamen

Equipped with the domestically developed "Jifengdao" accelerator BNCT system; drug-device registration trials underway, only 1-2 sessions needed.

About the Hospital

Xiamen Humanity Hospital is a large grade-A tertiary non-profit general hospital founded by the C&D Group, focusing on oncology and rare diseases. It has established China’s first accelerator-based BNCT clinical center and is the pioneer of BNCT clinical translation in China.

Built to international JCI standards and equipped with PET/CT, TOMO and other advanced systems, the hospital’s cancer center runs routine MDTs and offers multilingual services with hotel-grade inpatient environments for international patients.

Hospital Strengths

01China’s BNCT clinical center

It completed the full chain of BNCT equipment, boron drugs, dose planning and clinical workflows, and launched registered clinical studies first in China — recurrent head-and-neck tumor patients are the main beneficiaries.

02International service standards

JCI-standard construction, a multilingual service team and international insurance experience deliver a smooth care experience for overseas patients.

03Precision radiotherapy platform

High-end platforms including TOMO and EDGE support high-precision irradiation of complex sites.

Key Departments

BNCT CenterCancer CenterRadiation OncologyNuclear MedicineMedical Oncology

Coordinated Treatment Directions

  1. 01BNCT clinical studies for recurrent head-neck tumors
  2. 02Precision radiotherapy (TOMO) for complex sites
  3. 03MDT care for rare diseases and difficult tumors
  4. 04Full-journey services for international patients

Officially Reported Treatment Milestones

Mainland China’s first accelerator-based BNCT human clinical study

2022

Built mainland China’s first accelerator-based boron neutron capture therapy (BNCT) center and completed treatment of the first human study participants, offering a new option for recurrent head and neck tumors.

Cross-border care collaboration base in the Boao Lecheng pilot zone

2021–

Collaborates with the Boao Lecheng pilot zone on early access to international innovative therapies, allowing domestic patients to receive treatments not yet approved in China.

Accreditations & Platforms

  • China’s first and the world’s largest single-site accelerator BNCT center
  • National clinical trial site for oncology drugs & devices